ReviewThe pharmacogenomics journal2008
Ancillary risk information and pharmacogenetic tests: social and policy implications.
Review in The pharmacogenomics journal, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Disclosing Pleiotropic Effects During Genetic Risk Assessment for Alzheimer Disease: A Randomized Trial.Annals of internal medicine · 2016Trial
- Pharmacotherapy Risks in Rare Genetic Diseases: Cross-Referencing ACMG Secondary Findings v3.2 List With Clinical Databases.Clinical and translational science · 2026Article
- Pharmacogenetics in ICU patients: a short introduction.Intensive care medicine · 2025Article
- Personalizing Personalized Medicine: The Confluence of Pharmacogenomics, a Person's Medication Experience and Ethics.Pharmacy (Basel, Switzerland) · 2023Review
- Revisiting Secondary Information Related to Pharmacogenetic Testing.Frontiers in genetics · 2021Article
- Pharmacogenomics--how close/far are we to practising individualized medicine for children?British journal of clinical pharmacology · 2015Article
- Understanding patient and provider perceptions and expectations of genomic medicine.Journal of surgical oncology · 2015Review
- Personalized sequencing and the future of medicine: discovery, diagnosis and defeat of disease.Pharmacogenomics · 2014Article
- Comparison of delivery strategies for pharmacogenetic testing services.Pharmacogenetics and genomics · 2014Review
- Returning pleiotropic results from genetic testing to patients and research participants.JAMA · 2014Article
- A closer look at the recommended criteria for disclosing genetic results: perspectives of medical genetic specialists, genomic researchers, and institutional review board chairs.Journal of genetic counseling · 2013Article
- Clinical delivery of pharmacogenetic testing services: a proposed partnership between genetic counselors and pharmacists.Pharmacogenomics · 2013Article
- Implementation of a clinical research pharmacogenomics program at an academic medical center: role of the genetics healthcare professional.Pharmacogenomics · 2013Article
- Mapping the incidentalome: estimating incidental findings generated through clinical pharmacogenomics testing.Genetics in medicine : official journal of the American College of Medical Genetics · 2013Review
- Delivering pharmacogenetic testing in a primary care setting.Pharmacogenomics and personalized medicine · 2013Article
- Genetics specialists' perspectives on disclosure of genomic incidental findings in the clinical setting.Patient education and counseling · 2013Article
- Survey of genetic counselors and clinical geneticists' use and attitudes toward pharmacogenetic testing.Clinical genetics · 2012Article
- Public perspectives about pharmacogenetic testing and managing ancillary findings.Genetic testing and molecular biomarkers · 2012Article
- Professional perspectives about pharmacogenetic testing and managing ancillary findings.Genetic testing and molecular biomarkers · 2012Article
- Public attitudes toward ancillary information revealed by pharmacogenetic testing under limited information conditions.Genetics in medicine : official journal of the American College of Medical Genetics · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Some pharmacogenetic tests may provide ancillary disease risk information. To evaluate evidence and assess the social and policy implications of ancillary disease risk information associated with candidate pharmacogenetic variants, We conducted a literature search and abstract review of disease susceptibility studies for each of 42 gene variants potentially associated with drug response. Twenty-two variants (53%) had suggested association with disease risk in at least two studies, and sixteen (38%) were for diseases other than the pharmacogenetic indication. Seven variants (16%) were associated with risk for at least two different diseases. Pharmacogenetic tests have the potential to provide ancillary disease risk information, and this potential should be considered as pharmacogenetic tests are brought into clinical use. Implications will vary with each test but tests should be evaluated individually within a framework that outlines the potential implications of ancillary information.
Indexed as
Identifiers
17486108What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.